Register Free
Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1003 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1003 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington’s Disease
HDClarity collects spinal fluid and blood samples from 2500 Huntington's disease patients to identify biomarkers for developing new treatments.
27 Apr 2026 NCT02855476
active not recruiting Phase II
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
A trial testing a new cell therapy (tabelecleucel) to treat diseases caused by Epstein-Barr virus infection.
27 Apr 2026 NCT04554914
● Recruiting Phase II / Phase III
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
Frexalimab injections compared to tacrolimus tablets in first kidney transplant patients over five years to assess effectiveness and safety.
27 Apr 2026 NCT07412470
● Recruiting Phase I / Phase II
A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
Testing whether adding roginolisib to ruxolitinib safely improves outcomes in myelofibrosis patients who haven't responded to JAK inhibitors alone.
27 Apr 2026 NCT06887803
● Recruiting Phase III Rheumatology
OLE Study With Filgotinib in JIA
Filgotinib appears safe and effective for long-term use in children with polyarticular or systemic juvenile idiopathic arthritis.
27 Apr 2026 NCT07553182
active not recruiting Phase IV
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
Emicizumab treatment improves health, physical activity, and joint damage in teenagers and adults with moderate to severe haemophilia A.
27 Apr 2026 NCT05181618
active not recruiting Dermatology
A Proof-of-Concept Study to Evaluate the Efficacy of NOBO, a Novel Postbiotic, in Controlling Axillary Odor in Healthy Adults
Trial testing whether a yeast-based spray reduces underarm odor compared to placebo in healthy adults.
27 Apr 2026 NCT07547761
● Recruiting Gastroenterology
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize…
27 Apr 2026 NCT04883905
● Recruiting Phase II Rheumatology
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis
This trial aims to find out if obe-cel gets rid of harmful B cells that contribute to systemic lupus erythematosus (SLE)/lupus nephritis (LN) when…
27 Apr 2026 NCT07053800
● Recruiting Phase III Cardiology / Cardiovascular
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
Roxadustat is a licensed medicine to treat anemia in adults with chronic kidney disease (CKD). Anemia is a low level of red blood cells.…
27 Apr 2026 NCT05970172
● Recruiting Phase III Infectious Disease
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
This randomized, open-label, parallel group, two-arm, multi-center assessment will compare IV BCV with IV CDV in adult and pediatric allogeneic HCT recipients with AdV…
27 Apr 2026 NCT07387367
● Recruiting Rheumatology
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
27 Apr 2026 NCT07177209
● Recruiting Phase III Oncology
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
The primary objective of the study is to assess the efficacy in terms of CNS-specific PFS of the combination of standard systemic treatment plus…
27 Apr 2026 NCT05522660
● Recruiting Cardiology / Cardiovascular
Hydra Registry – UK
The study will evaluate the efficacy and safety of transcatheter aortic valve implantation (TAVI) using the Hydra transcatheter aortic heart valve (THV) series, in…
27 Apr 2026 NCT06507579
● Recruiting Phase II Cardiology / Cardiovascular
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess the efficacy and safety of ninerafaxstat compared to placebo on…
27 Apr 2026 NCT07023614
● Recruiting Cardiology / Cardiovascular
Mayo AVC Registry and Biobank
Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden…
27 Apr 2026 NCT03049254
● Recruiting Phase II Oncology
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for…
27 Apr 2026 NCT05882058
● Recruiting Phase III Oncology
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic…
27 Apr 2026 NCT07522073
● Recruiting Phase III Oncology
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) /…
27 Apr 2026 NCT04892173
● Recruiting Phase II Oncology
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
The purpose of this study is to measure the pharmacokinetics (PK), pharmacodynamics (PD), safety, tolerability, and immunogenicity of efgartigimod PH20 SC in pediatric participants…
27 Apr 2026 NCT06392386
● Recruiting Phase I / Phase II
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Trial testing two new cell therapies (KITE-363 and KITE-753) for B-cell lymphoma that hasn't responded to standard treatment.
24 Apr 2026 NCT04989803
● Recruiting Phase III
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
New anti-inflammatory injection (itepekimab) tested alongside steroid nasal spray for difficult-to-treat nasal polyps over one year.
24 Apr 2026 NCT06834360
active not recruiting Phase II
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
A trial testing whether tebapivat reduces blood transfusion needs in patients with low-risk bone marrow disorders.
24 Apr 2026 NCT05490446
● Recruiting Phase III
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
ION582 improved seizures, sleep and developmental outcomes in Angelman syndrome patients with UBE3A deletions or mutations.
24 Apr 2026 NCT06914609
active not recruiting Phase II / Phase III
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
Diacerein ointment tested for safety and effectiveness in treating generalized epidermolysis bullosa simplex blistering disorder.
24 Apr 2026 NCT06073132
active not recruiting Phase I / Phase II Oncology
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
Trial testing durvalumab combinations versus standard chemotherapy in patients with advanced triple negative breast cancer.
24 Apr 2026 NCT03742102
● Recruiting Phase II Dermatology
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
Trial testing different doses of galvokimig versus placebo in adults with moderate-to-severe eczema to find the most effective safe dose.
24 Apr 2026 NCT07277660
● Recruiting Phase I
A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
Andexanet alfa dosing study examining how it interacts with subsequent enoxaparin treatment in healthy volunteers.
24 Apr 2026 NCT07312851
active not recruiting Phase I
Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma
A trial testing a new engineered cell therapy for children with difficult-to-treat neuroblastoma, focusing on safety and feasibility.
24 Apr 2026 NCT05990751
active not recruiting Phase I Infectious Disease
COVID-19 Omicron BA.5 Subvariant Dose Finding Infection Study
Researchers tested different doses of Omicron BA.5 virus in vaccinated volunteers to find the optimal dose for future COVID vaccine studies.
24 Apr 2026 NCT06478420
● Recruiting Phase III Gastroenterology
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
What is being tested: Efruxifermin (EFX), an FGF21 analogue, is being evaluated in a randomized controlled trial to assess its efficacy and safety in…
24 Apr 2026 NCT06528314
● Recruiting Phase II Respiratory / COPD / Asthma
Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
What is being tested: Imlifidase, an IgG-degrading enzyme, is being evaluated for its efficacy and safety in enabling successful kidney transplantation in highly sensitized…
24 Apr 2026 NCT05753930
● Recruiting Phase III Cardiology / Cardiovascular
A Study of Migalastat in Pediatric Subjects (2 to
What is being tested: Migalastat, a pharmacological chaperone, is being evaluated for safety, pharmacokinetics, pharmacodynamics, and efficacy in treating paediatric Fabry disease patients aged…
24 Apr 2026 NCT06904261
● Recruiting Cardiology / Cardiovascular
Neurovascular Product Surveillance Registry
What is being tested: This is a post-market surveillance registry monitoring the safety and performance of neurovascular products already in clinical use, rather than…
24 Apr 2026 NCT02988128
● Recruiting Phase IV Cardiology / Cardiovascular
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
Treatment being tested: Thromboprophylaxis (blood clot prevention strategies) in patients undergoing endovenous interventions for superficial varicose veins, which are minimally invasive keyhole procedures performed…
24 Apr 2026 NCT05735639
● Recruiting Phase I Oncology
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
What is being tested: Novel treatment combinations pairing enfortumab vedotin with pembrolizumab, investigating whether additional agents can improve outcomes in locally advanced or metastatic…
24 Apr 2026 NCT07232602
● Recruiting Phase III Oncology
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
What is being tested: ARTEMIDE-Lung04 evaluates rilvegostomig (a novel immunotherapy agent) versus pembrolizumab monotherapy as first-line treatment in patients with metastatic non-small cell lung…
24 Apr 2026 NCT06868277
● Recruiting Phase II Oncology
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
What is being tested: Pumitamig (BNT327), a novel investigational therapy, combined with chemotherapy as first-line or second-line treatment in advanced/metastatic NSCLC, with evaluation of…
24 Apr 2026 NCT06841055
● Recruiting Phase III Oncology
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
What is being tested: Mocravimod, a TLR7 agonist, is being evaluated as an adjunctive and maintenance therapy in acute myeloid leukaemia (AML) patients undergoing…
24 Apr 2026 NCT05429632
● Recruiting Phase III Oncology
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
What is being tested: Long-term safety and efficacy of pembrolizumab (an anti-PD-1 immunotherapy) in patients with advanced tumors who are continuing treatment or follow-up…
24 Apr 2026 NCT03486873
● Recruiting Phase II / Phase III
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
A trial testing whether an oral cholesterol-lowering drug is safe and effective in children and teenagers with familial high cholesterol.
23 Apr 2026 NCT07058077
active not recruiting Phase III Oncology
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Osimertinib after surgery improves survival in early-stage lung cancer patients with specific EGFR mutations.
23 Apr 2026 NCT05120349
active not recruiting Phase II / Phase III
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
Mitapivat tested in sickle cell patients to increase haemoglobin levels and reduce painful crisis episodes compared to placebo.
23 Apr 2026 NCT05031780
active not recruiting Phase II
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
Trial testing tebapivat against placebo in sickle cell disease patients to find the best dose for improving hemoglobin levels.
23 Apr 2026 NCT06924970
active not recruiting Rheumatology
The UK ADAPTIS Study
Study evaluating a new ankle replacement implant design in NHS patients to assess its performance and durability.
23 Apr 2026 NCT06941558
● Recruiting Phase III Gastroenterology
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
Trial testing a new drug (Afimkibart) for treating moderate-to-severe ulcerative colitis in children, measuring safety and effectiveness.
23 Apr 2026 NCT07158242
active not recruiting Phase II Rheumatology
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
A new drug (LY3871801) is being tested for safety and effectiveness in adults with moderate-to-severe rheumatoid arthritis.
23 Apr 2026 NCT05848258
● Recruiting Phase II Respiratory / COPD / Asthma
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
What is being tested: KT-621, an oral investigational agent, is being evaluated in a Phase 2b trial to assess its safety and efficacy in…
23 Apr 2026 NCT07323654
● Recruiting Phase III Respiratory / COPD / Asthma
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
What is being tested: Depemokimab, a monoclonal antibody, is being evaluated for its effects on airway structure and function in asthma patients using imaging…
23 Apr 2026 NCT06979323
● Recruiting Phase IV Respiratory / COPD / Asthma
Dosing of Steroids for Acute Asthma Given in the Emergency Department – a Pilot Randomised Feasibility Trial of Dexamethasone in Children
What is being tested: A pilot feasibility trial comparing dexamethasone (single-dose steroid) versus standard oral steroids for treating acute asthma exacerbations in children presenting…
23 Apr 2026 NCT07402707